Skip to main content

How can we help you?

  • Deal or case news
  • 14-02-2018

Yesterday evening, Merus, a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), signed a deal with BVF Partners, Aquilo, Sofinnova and LSP on a USD 55.8 million PIPE.

The deal will close later this week. We are roud to have acted as Dutch counsel to Merus, alongside Latham & Watkins.

The NautaDutilh team was led by Paul van der Bijl, with invaluable support from Jules van de Winckel, Philip Silvis and Arief Roelse.

Merus published an official press release on its website.

Cookie notice

Our website only uses cookies when you play video content. Video content is streamed from Vimeo. Our website does not use tracking cookies and/or third party cookies when you do not play video content. Please read the privacy/cookie policy for more information.